Product Specifications [Leu24][Ala31]IGF-I:

[Leu24][Ala31]IGF-I is an analog of human IGF-I with a substitution of Leu for Tyr at position 24 and an Ala for Tyr at position 31 of the human IGF-I sequence. [Leu24][Ala31]IGF-I has greatly reduced binding to the Type 1 IGF receptor compared to IGF-I, and a lower affinity than [Leu24]IGF-I or [Leu60]IGF-I. However [Leu24][Ala31]IGF-I has normal binding to acid-stripped human serum binding proteins. Consequently [Leu24][Ala31]IGF-I is an extremely useful analog of IGF-I for investigating IGF actions largely independent of binding to the Type 1 IGF receptor.
Source: [Leu24][Ala31]IGF-I is produced recombinantly as a fusion protein in E.coli using a patented expression system. The fusion protein containing [Leu24][Ala31]IGF-I is refolded, and after the leader peptide is removed, the [Leu24][Ala31]IGF-I product is purified to Receptor Grade using several chromatography steps.

Purity: > 95% (as determined by HPLC and N-terminal sequence analysis)

Molecular weight:Theoretical : 7507 daltons. Confirmed by Mass Spect rometry.

Appearance:Lyophilized white powder

N-terminal sequence analysis:5 residues > 95% single sequence

Endotoxin (LAL): < 0.1 EU/µg

Biological Activity:Type 1 IGF receptor binding assay - ED50 > 750 ng/ml. IGF binding protein assay - ED50 < 10 ng/ml.

Stimulation of protein synthesis in rat L6 myoblasts -  ED50 > 2000 ng/ml.

State: Dried from 0.1 M acetic acid and stored under dry nitrogen at a slight vacuum (-25kPa).

Reconstitution: Dissolve in dilute acid (e.g. 10mM HCl or 0.1M acetic acid), aliquot and store at -20°C. For lower dilutions (e.g. < 1mg/ml) inclusion of a carrier protein is recommended. Avoid freeze-thaw cycles.

Storage/Stability: At least 2 years at 2-4°C (lyophilized)

Peptide can be biotinylated by ibt upon request.

This is a Gropep specification. ibt is authorized distributor of GroPep.

Rev. 2013-02

 Datasheet for (Leu24)(Ala31)IGF-I, recombinant protein (Receptor Grade)